British Columbia Cancer Agency, Vancouver Island Centre, University of British Columbia, 2410 Lee Avenue, Victoria, BC, V8R 6V5, Canada.
Expert Rev Anticancer Ther. 2010 Aug;10(8):1229-38. doi: 10.1586/era.10.87.
In the modern era of breast-conserving therapy for early-stage breast cancer, ipsilateral breast tumor recurrence (IBTR) represents an increasingly common clinical dilemma. Two kinds of IBTRs have been described: true recurrences, which represent regrowth of uneradicated initial disease, and new primaries, which may be distinct from the index lesion in histology and location. Whether these two entities have different biologies and survival prognoses remains unclear. This article will examine contemporary clinical and pathologic methods to distinguish true recurrence from new primary tumors, focusing on available published data from prospective and retrospective studies. Current challenges and future avenues are discussed for developing a standardized, reproducible classification system for different types of IBTR that may be used in the clinical setting to prognosticate and individualize treatment for patients following in-breast recurrences.
在早期乳腺癌保乳治疗的现代时代，同侧乳房肿瘤复发 (IBTR) 代表了一种日益常见的临床困境。已经描述了两种 IBTR：真性复发，代表初始疾病未被根除的再生；以及新原发性肿瘤，其在组织学和位置上可能与原发灶不同。这两种实体是否具有不同的生物学和生存预后尚不清楚。本文将探讨当代临床和病理方法来区分真性复发和新原发性肿瘤，重点是来自前瞻性和回顾性研究的现有发表数据。讨论了当前的挑战和未来的途径，以开发一种用于不同类型 IBTR 的标准化、可重复的分类系统，该系统可用于临床环境中，为乳房内复发患者的预后和个体化治疗提供依据。
